Rheumatoid Arthritis Clinical Trial
Official title:
Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes.
The aim of the study is to evaluate cardiovascular events during long-term follow-up in Rheumatoid Arthritis. The primary outcome "any cardiovascular event" will be evaluated using systematic audits of patient records, and will be associated to low levels of vitamin D at baseline, to investigate the hypothesis that low levels of vitamin D can be part of a prediction model for cardiovascular disease in Rheumatoid Arthritis.
Status | Completed |
Enrollment | 160 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: Fulfilling ACR1987 (American College of Rheumatology 1987
classification criteria for Rheumatoid Arthritis) criteria for RA, disease duration < 6
months, 2 or more swollen joints and age between 18 and 75 years - Exclusion Criteria: Glucocorticoid treatment 4 weeks prior to inclusion, previous use of DMARDs, malignancy, diastolic blood pressure > 90 mm Hg, elevated serum creatinine, infections with parvovirus B19, Hepatitis B, C and HIV, and any condition contraindicating the study medication. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Odense University Hospital | Odense Patient Explorative data Network (OPEN), Pfizer, Region of Southern Denmark, The Danish Rheumatism Association, University of Southern Denmark |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiovascular event | Events will be recorded using systematic journal audits. A cardiovascular event will be further subclassified as shown in the secondary outcome measures, but for primary outcome measures; any cardiovascular event, including death, will serve as "an event" | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to Myocardial Ischamia | Non-fatal or fatal myocardial infarction, defined by National and International Guidelines (Thygesen et al. 1581-98). Fatal myocardial infarction is defined as primary fatal event within 7 days, documented post mortem by autopsy, or by the definition of myocardial infarction according to European Guidelines (Thygesen et al. 1581-98) Death of myocardial infarction as a consequence of medical examination/procedure/surgery will be classified as procedure related death. Acute Coronary Syndrome (ACS) includes acute ischaemic symptoms with eventual elevation in biomarkers or electrocardiographic changes which does not fulfil the criteria of acute myocardial infarction. Angina Pectoris. Revascularisation procedures (Percutaneous Coronary Intervention (PCI) or Coronary bypass Graft (CABG). |
Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to hearth failure | Patients with non-elective hospitalisation or death, minimum one overnight stay, with symptoms or findings of heart failure. Death due to heart failure is defined as escalating heart failure symptoms prior to death. |
Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to stroke | Cerebral haemorrhage, cerebral thromboembolism, Transitory Cerebral Ischemia (TCI) and others Stroke is defined as abrupt severe neurologic deficits, eventually with computer tomographic (CT) documentation. Death within 14 days after symptom-onset of stroke, and without other obviously reasons, is classified as caused by stroke | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to arrhythmias | Atrial fibrillation or flutter, supraventricular tachycardia and others. Ventricular tachycardia, ventricular fibrillation and others. Death due to arrhythmia requires documentation, e.g. telemetric transcript, pacemaker or electrocardiogram | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to Procedure-related cardiovascular event | Any cardiovascular event within 24 hours after cardiovascular medical examination/procedure/surgery. | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to other reasons | Hospitalisation caused by other cardiovascular events, e.g. pulmonary embolism, rupture of aortic aneurism etc. | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute cardiovascular hospitalisation due to supposed cardiovascular reason | Hospitalisation without any documented non-cardiovascular cause. All deaths which are not defined by the cardiovascular reasons mentioned above, and who are not caused by well-documented non-cardiovascular death. All deaths without known reason |
Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to cancer | Acute hospitalisation due to cancer | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to infection | Acute hospitalisation due to infection | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to respiratory disease | Acute hospitalisation due to respiratory disease | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to trauma | Acute hospitalisation due to trauma | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to suicide | Acute - hospitalisation due to suicide | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Acute non-cardiovascular hospitalisation due to other reasons | Acute hospitalisation du to other non-cardiovascular reasons, than those previous mentioned | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Elective cardiovascular hospitalisation due to myocardial ischemia | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective cardiovascular hospitalisation due to arrhythmia | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective cardiovascular hospitalisation due to heart failure | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective cardiovascular hospitalisation due to other cardiovascular reasons | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective non-cardiovascular hospitalisation due to cancer | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective non-cardiovascular hospitalisation due to infection | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective non-cardiovascular hospitalisation due to respiratory disease | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective non-cardiovascular hospitalisation due to trauma | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Elective non-cardiovascular hospitalisation due to suicide | Observed in the time-period from inclusion to October the 10th 2016 | No | |
Secondary | Witnessed, sudden cardiovascular death | Death is witnessed and abrupt within one hour after symptom-onset | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Non-witnessed, sudden cardiovascular death | Non-witnessed death with no obvious non-cardiovascular reasons (found death) | Observed in the time-period from inclusion to October the 10th 2016 | No |
Secondary | Non-sudden cardiovascular death | Death due to any of the cardiovascular caused previously mentioned, more than one hour after symptom-onset | Observed in the time-period from inclusion to October the 10th 2016 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |